220844-53-1

Basic information

• Product Name: 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester
• Synonyms: 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester
• CAS NO: 220844-53-1
• Molecular Weight: 372.216
• Mol File: 220844-53-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester(220844-53-1)
• EPA Substance Registry System: 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester(220844-53-1)

Safety Data

• Hazardous Substances Data: 220844-53-1(Hazardous Substances Data)

Upstream product

• 5344-78-5 4-bromo-3-nitroanizole 

Downstream Products

• 873054-97-8 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 145209-64-9 9-Methoxy-2-phenyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one 
• 145209-65-0 9-Hydroxy-2-phenyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one 
• 161405-29-4 ethyl 8-bromo-5-methoxy-4-oxoquinolin-3-carboxylic acid 
• 161405-25-0 ethyl 8-bromo-5-methoxy-4-oxoquinolin-3-carboxylate 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.